Product Description
ACT-01 is a peptidomimetic first-in-class disease-modifying treatment for multiple sclerosis (MS) and acute optic neuritis,. It crosses the blood-brain barrier by active transport, to promote neuronal cell survival and myelination
Mechanisms of Action: PAI-1 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abyss Ingredients
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Optic Neuritis|Keratosis, Actinic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06268847 |
DERMATIDYSS | N/A |
Completed |
Dermatitis, Atopic |
2024-04-02 |
2024-08-22 |
||
2020-003147-29 |
2020-003147-29 | P2 |
Completed |
Optic Neuritis |
2022-11-06 |
31% |
2025-05-06 |
Treatments|Trial Status |
NCT02126670 |
NP1401 | P2 |
Completed |
Keratosis, Actinic |
2014-09-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|